This SuperSeries is composed of the SubSeries listed below.
Overall design: Refer to individual Series
| Accession | PRJNA343770; GEO: GSE87164 |
| Type | Umbrella project |
| Publications | Guerriero JL et al., "Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.", Nature, 2017 Mar 16;543(7645):428-432 |
| Submission | Registration date: 21-Sep-2016
Tempero DPU, GSK |
| Relevance | Superseries |
Project Data:
| Resource Name | Number
of Links |
|---|
| Publications |
| PubMed | 1 |
| PMC | 1 |
| Other datasets |
| GEO DataSets | 3 |
GEO Data Details| Parameter | Value |
|---|
| Data volume, Spots | 503545 |
| Data volume, Processed Mbytes | 9 |
| Data volume, Supplementary Mbytes | 75 |
Gene expression in MMTV-PyMT whole tumor, CD3+ lymphocytes or CD11b+ myeloid cells with and without Class IIa HDAC inhibitor treatment encompasses the following 2 sub-projects:
| Project Type | Number of Projects |
| Transcriptome or Gene expression | 2 |
BioProject
accession | Organism | Title |
|---|
| PRJNA308242 | Mus musculus | Differential gene expression in either CD3+ lymphocytes or CD11b+ myeloid cells due to Class IIa HDAC inhibitor treatment (Tempero DPU, GSK) | | PRJNA343769 | Mus musculus | MMTV-PyMT whole tumor gene expression with and without Class IIa HDAC inhibitor treatment (Tempero DPU, GSK) |
|